MInjie Wang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Minjie Wang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Inner Mongolia Medical University | China

Prof. Minjie Wang is an accomplished biomedical researcher with a strong scholarly record, reflected by an h-index of 6, 15 peer-reviewed documents, and 93 citations. His research focuses on the discovery and functional characterization of active substances from Traditional Chinese Medicine and Mongolian Medicine, with particular emphasis on the pathological mechanisms of cardiovascular and cerebrovascular diseases and the identification of therapeutic drug targets. A major theme of his work is the role of AMP-activated protein kinase (AMPK) in vascular inflammation, endothelial dysfunction, atherosclerosis, metabolic syndrome, and adipose tissue remodeling. His studies integrate advanced in vivo animal models—including atherosclerosis, myocardial ischemia-reperfusion injury, arrhythmia, and cerebral ischemia—with comprehensive in vitro approaches encompassing cell culture, molecular biology, immunohistochemistry, and biochemical analysis. Prof. Wang has published extensively in high-impact journals such as European Heart Journal, Cell Death & Disease, Frontiers in Microbiology, Acta Pharmacologica Sinica, and European Journal of Pharmacology, contributing significant insights into vascular biology, inflammation, metabolism, and translational pharmacology. His work also includes patented innovations related to AMPK activators for vascular inflammation and endothelial protection, underscoring both scientific depth and translational relevance.

 

Citation Metrics (Scopus)

10080

60

40

20

0

Citations
93

Documents
15

h-index
6

Citations

Documents

h-index


View Scopus Profile

Featured Publications

 

Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.

Zhuowei Luo | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Mr. Zhuowei Luo | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Hubei University of Chinese Medicine | China

Mr. Zhuowei Luo is an emerging researcher recognized for effectively integrating classical Traditional Chinese Medicine (TCM) theory with modern biomedical science, demonstrating strong expertise in molecular mechanism analysis and advanced metabolomics for chronic disease research. His notable scientific contribution is a co-authored publication in the Journal of Ethnopharmacology (Q2, IF 5.14), where he helped elucidate how Allium macrostemon delays chronic renal failure by modulating the IL-17 signaling pathway and altering tryptophan and glycerophospholipid metabolism. This work represents the first comprehensive study connecting immunological regulation with multi-omics profiling to explain the therapeutic mechanisms of this TCM herb, providing a meaningful model for modernizing traditional medicine through systems biology. His role in the project included designing and validating qPCR primers, conducting network pharmacology to identify key molecular targets, performing metabolomics and transcriptomics data analyses, and carrying out histopathological assessments. Through these contributions, he demonstrated an advanced ability to apply interdisciplinary approaches—combining immunology, pharmacology, and bioinformatics—to uncover mechanistic insights into natural product–based interventions. His research reflects scientific maturity beyond typical early-stage experience and contributes to the growing evidence supporting data-driven modernization of TCM in chronic disease treatment.

Profile : Orcid

Featured Publication

Zhao, Y., Ge, J. X., Zhang, N., Lei, Z. X., Sun, S. Y., Luo, Z. W., Yang, Y. F., & Wu, H. Z. (2025). Allium macrostemon Bge. delays chronic renal failure by modulating IL-17 signaling pathway and affecting tryptophan/glycerophospholipid metabolism. Journal of Ethnopharmacology, 120946.

Annalisa Bosi | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Annalisa Bosi | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

University of Insubria | Italy

Dr. Annalisa Bosi is a distinguished researcher with 909 citations, 29 scientific documents, and an h-index of 15, reflecting her strong impact in the fields of immunology, gastrointestinal pathology, and microbiota–gut–brain axis research. Her early work focused on the phenotypic and functional characterization of innate immune components, particularly NK cells and macrophages, examining their role in tumor pathogenesis and their modulation by chemotherapeutic agents or plant-derived molecules. She later advanced her research to explore molecular and cellular mechanisms underlying major gastrointestinal diseases such as ischemia, intestinal inflammation, and enteric neuropathy, identifying the regulatory role of hyaluronic acid homeostasis in tissue repair. Her recent studies investigate gut microbiota, dysbiosis, and their influence on neurodevelopment and tumor etiopathogenesis, with growing emphasis on prebiotic and probiotic interventions. Dr. Bosi has contributed significantly to understanding experimental models of gut pathology, neuromuscular dysfunction, immunomodulation by virome components, and sex-dependent microbial effects. Her publications span high-impact journals, covering topics such as microbiota–immune interactions, ischemia–reperfusion injury, cytokine–phage crosstalk, and neuroimmune modulation. Through multidisciplinary approaches integrating molecular biology, immunology, and neurogastroenterology, her work continues to shape emerging perspectives on host–microbiota communication and its relevance to disease mechanisms and therapeutic strategies.

Profiles : Scopus | Orcid

Featured Publications

Bosi, A., Baranzini, N., Ponti, A., Moretto, P., Moro, E., Crema, F., Cianci, R., Karousou, E., Viola, M., Passi, A., et al. (2025). Intestinal ischemia/reperfusion injury influences hyaluronan homeostasis in the rat brain. International Journal of Molecular Sciences, 26(20), 10064.

Cianci, R., Caldarelli, M., Brani, P., Bosi, A., Ponti, A., Giaroni, C., & Baj, A. (2025). Cytokines meet phages: A revolutionary pathway to modulating immunity and microbial balance. Biomedicines, 13(5), 1202.

Faggin, S., Cerantola, S., Caputi, V., Tietto, A., Stocco, E., Bosi, A., Ponti, A., Bertazzo, A., Macchi, V., Porzionato, A., et al. (2025). Toll-like receptor 4 deficiency ameliorates experimental ileitis and enteric neuropathy: Involvement of nitrergic and 5-hydroxytryptaminergic neurotransmission. British Journal of Pharmacology, 182(8), 1803–1822.

Brani, P., Manzoor, H. Z., Spezia, P. G., Vigezzi, A., Ietto, G., Dalla Gasperina, D., Minosse, C., Bosi, A., Giaroni, C., Carcano, G., et al. (2025). Torque Teno Virus: Lights and shades. Viruses, 17(3), 334.

Dal Lago, S., Brani, P., Ietto, G., Dalla Gasperina, D., Gianfagna, F., Giaroni, C., Bosi, A., Drago Ferrante, F., Genoni, A., Manzoor, H. Z., et al. (2024). Torque Teno Virus: A promising biomarker in kidney transplant recipients. International Journal of Molecular Sciences, 25(14), 7744.

Giambra, V., Pagliari, D., Rio, P., Totti, B., Di Nunzio, C., Bosi, A., Giaroni, C., Gasbarrini, A., Gambassi, G., & Cianci, R. (2023). Gut microbiota, inflammatory bowel disease, and cancer: The role of guardians of innate immunity. Cells, 12(22), 2654.

Bosi, A., Banfi, D., Bistoletti, M., Catizzone, L. M., Chiaravalli, A. M., Moretto, P., Moro, E., Karousou, E., Viola, M., Giron, M. C., et al. (2022). Hyaluronan regulates neuronal and immune function in the rat small intestine and colonic microbiota after ischemic/reperfusion injury. Cells, 11(21), 3370.

Bosi, A., Banfi, D., Bistoletti, M., Moretto, P., Moro, E., Crema, F., Maggi, F., Karousou, E., Viola, M., Passi, A., et al. (2021). Hyaluronan: A neuroimmune modulator in the microbiota–gut axis. Cells, 11(1), 126.

Cerantola, S., Caputi, V., Contarini, G., Mereu, M., Bertazzo, A., Bosi, A., Banfi, D., Mantini, D., Giaroni, C., & Giron, M. C. (2021). Dopamine transporter genetic reduction induces morpho-functional changes in the enteric nervous system. Biomedicines, 9(5), 465.

Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M. C., Giaroni, C., & Baj, A. (2021). Impact of microbial metabolites on microbiota–gut–brain axis in inflammatory bowel disease. International Journal of Molecular Sciences, 22(4), 1623.

Baci, D., Bosi, A., Parisi, L., Buono, G., Mortara, L., Ambrosio, G., & Bruno, A. (2020). Innate immunity effector cells as inflammatory drivers of cardiac fibrosis. International Journal of Molecular Sciences, 21(19), 7165.

Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D. M., Poggi, A., Bruno, A., & Mortara, L. (2020). The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: A focus on innate immunity cells as therapeutic effectors. International Journal of Molecular Sciences, 21(9), 3125.

Bosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020). Tryptophan metabolites along the microbiota–gut–brain axis: An interkingdom communication system influencing the gut in health and disease. International Journal of Tryptophan Research, 13, 1–18.

Keon-Hyoung Song | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Prof. Dr. Keon-Hyoung Song | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Soonchunhyang University | South Korea

Prof. Dr. Keon-Hyoung Song is a distinguished researcher whose work bridges pharmaceutical sciences, drug delivery systems, and pharmacokinetics. With 708 citations, 27 scholarly publications, and an h-index of 13, his research has significantly advanced the understanding of membrane permeation enhancers, drug formulation, and solubilization strategies. His extensive portfolio includes high-impact studies on intestinal absorption mechanisms, cocrystal engineering, and pharmacokinetic optimization, published in reputed journals such as Pharmaceutics, European Journal of Medicinal Chemistry, and Journal of Controlled Release. Prof. Song’s innovations extend beyond academia, with over 25 international patents registered across the U.S., Europe, and Korea, focusing on permeation-enhancing peptides, liposomal carriers, and pharmaceutical formulations. His pioneering patents, including those on mucous membrane permeation peptides (EP 3875103, 2025) and sugar alcohol-based liposome compositions, underscore his role in translating laboratory discoveries into therapeutic applications. Licensed as both a Patent Attorney and a Pharmacist, he effectively integrates regulatory insight with scientific innovation. Prof. Song’s sustained contributions to quantitative drug analysis using LC-MS and formulation optimization have made him a leading figure in advancing next-generation drug delivery technologies and pharmaceutical development.

Profile : Scopus

Featured Publications

Jeong, D.-H., Kim, J.-W., & Song, K.-H. (2025). Improved intestinal permeation of cyclosporin A by FCIGRL-modified tight junction modulator in rats. Pharmaceutics, 17(11), 1395.

Park, G., Galdamez, A., Song, K.-H., Le, M., Kim, K., & Lin, J. H. (2024). Ethnic variation and structure–function analysis of tauopathy-associated PERK alleles. Israel Journal of Chemistry, 64(12).

Song, K.-H. (2024). Effect of tight junction-modulating FCIGRL-modified peptides on the intestinal absorption of doxorubicin in rats. Pharmaceutics, 16(5), 650.

Jiang, F.-L., Jeong, D.-H., Eom, S.-H., Lee, H.-M., Cha, B.-J., Park, J.-S., Kwon, R.-K., Nam, J.-Y., Yu, H.-S., Heo, S.-H., Kim, C.-H., & Song, K.-H. (2024). Effects of enteric-coated formulation of sodium bicarbonate on bicarbonate absorption and gastrointestinal discomfort. Nutrients, 16(5), 744.

Koo, N. R., Yoon, S., Song, K.-H., Baek, M. J., Jeon, S., & Im, J. (2024). Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy. European Journal of Medicinal Chemistry, 265, 116050.

Park, G., Xu, K., Chea, L., Kim, K., Safarta, L., Song, K.-H., Wu, J., Park, S., Min, H., Hiramatsu, N., Han, J., & Lin, J. H. (2023). Neurodegeneration risk factor EIF2AK3 (PERK) influences tau protein aggregation. The Journal of Biological Chemistry, 299(2), 102821.

Eom, Y. S., Jeong, D., Ryu, A.-R., Song, K.-H., Im, D. S., & Lee, M.-Y. (2022). Daphne odora exerts depigmenting effects via inhibiting CREB/MITF and activating AKT/ERK-signaling pathways. Current Issues in Molecular Biology, 44(8), 3312–3323.

Kim, H., Song, K.-H., Ambegaonkar, J. P., Chung, S., Jeon, K., Jiang, F. L., Eom, J. J., & Kim, C.-H. (2022). Two-megahertz impedance index prediction equation for appendicular lean mass in Korean older people. BMC Geriatrics, 22(1), 385.

Jiang, F., Tang, S., Eom, J.-J., Song, K.-H., Kim, H., Chung, S., & Kim, C.-H. (2022). Accuracy of estimated bioimpedance parameters with octapolar segmental bioimpedance analysis. Sensors, 22(7), 2681.

Yoon, Y. M., Lee, J. H., Song, K.-H., Noh, H., & Lee, S. H. (2020). Melatonin-stimulated exosomes enhance the regenerative potential of chronic kidney disease-derived mesenchymal stem/stromal cells via cellular prion proteins. Journal of Pineal Research, 68(3), e12632.

Lee, J. H., Yoon, Y. M., Song, K.-H., Noh, H., & Lee, S. H. (2020). Melatonin suppresses senescence-derived mitochondrial dysfunction in mesenchymal stem cells via the HSPA1L-mitophagy pathway. Aging Cell, 19(3), e13111.

Cha, S. J., Choi, H.-J., Kim, H.-J., Choi, E. J., Song, K.-H., Im, D. S., & Kim, K. (2020). Parkin expression reverses mitochondrial dysfunction in fused in sarcoma-induced amyotrophic lateral sclerosis. Insect Molecular Biology, 29(1), 56–65.*

Adarsh Kumar Shukla | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Adarsh Kumar Shukla | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Dr. Bhimrao Ramji Ambedkar Government Medical College | India

Author Profile

Scopus

Orcid

Google Scholar

 

Early Academic Pursuits

Dr. Adarsh Kumar Shukla laid the foundation of his academic journey with a strong inclination towards life sciences and biological research. Beginning with a degree in Biotechnology, he cultivated a passion for understanding molecular processes and biological systems. His interest in computational and applied biological sciences further deepened during his Master’s studies in Bioinformatics, where he explored the integration of biology with computational technologies. This academic progression culminated in a doctoral degree in Nutrition Biology from the Central University of Haryana, where he investigated nutraceutical compounds, molecular therapeutics, and bioinformatics-based approaches to health and nutrition. His early academic pursuits reflect a strong balance between theoretical learning, laboratory training, and computational applications in life sciences.

Professional Endeavors

Dr. Shukla’s professional career demonstrates a consistent alignment with advanced biomedical research and innovation. He began as a Research Associate and later served as a Scientist in the Department of Paediatric Cardiac Research at Sri Sathya Sai Sanjeevani Research Foundation, contributing to projects on congenital heart diseases and molecular mapping of environmental toxicants. His current role as Scientist-B in the Multidisciplinary Research Unit at Dr. Bhimrao Ramji Ambedkar Government Medical College, Kannauj, highlights his continued commitment to translational biomedical research. Alongside, he has engaged in teaching and faculty development programs, coordinated national scientific conclaves, and participated in capacity-building initiatives in healthcare and nutrition sciences.

Contributions and Research Focus

Dr. Shukla’s research spans a wide spectrum, encompassing structural bioinformatics, human genomics, and nutritional biology. His investigations range from identifying novel bioactive compounds in millets and medicinal plants to computationally mapping toxicants responsible for congenital disorders. His work on psychobiotics and gut-brain regulation has added new insights into neuropsychological health, while his contributions in plant-informatics shed light on the therapeutic potential of natural compounds against viral and bacterial diseases. Additionally, his focus on food-informatics and nutrigenomics has emphasized the role of probiotics, dietary fibers, and bioengineered foods in human health. Through a combination of in-silico and in-vitro studies, his work bridges computational biology with clinical and nutritional sciences.

Accolades and Recognition

Over the course of his career, Dr. Shukla has been recognized for his scientific excellence through awards, patents, and international presentations. He achieved distinction at global scientific forums, securing recognition for his molecular insights into congenital heart disease. His granted Indian patent on crab-apple-based jelly sheets demonstrates his inventive ability to connect traditional resources with modern food biotechnology. Furthermore, his peer-review contributions for high-impact journals and invited roles as a book reviewer underline his standing in the academic community. These achievements illustrate his ability to merge innovation with scholarly rigor.

Impact and Influence

The impact of Dr. Shukla’s research is evident in the interdisciplinary nature of his contributions. His computational models for drug discovery, therapeutic peptides, and congenital heart disease targets provide frameworks for future translational research. His coordination of events such as National Nutrition Month and Women in STEM conclaves reflects his commitment to societal awareness and academic empowerment. By blending computational biology with real-world health challenges, he has influenced research directions in reproductive toxicology, nutraceutical development, and environmental genomics, thereby shaping both scientific knowledge and public health practices.

Legacy and Future Contributions

Dr. Shukla’s academic and professional trajectory reflects the making of a researcher whose work is deeply rooted in societal relevance and interdisciplinary innovation. His legacy lies in advancing computational nutrition biology and medical informatics to address complex health challenges. Looking ahead, his ongoing projects on congenital heart disease, exposome mapping, and nutratherapeutics hold the promise of contributing to precision medicine and sustainable food innovations. His future contributions are likely to expand the integration of bioinformatics with clinical sciences, reinforcing his role as a bridge between molecular insights and healthcare applications.

Present Affiliation

Dr. Adarsh Kumar Shukla is currently serving as Scientist-B in the Multidisciplinary Research Unit at Dr. Bhimrao Ramji Ambedkar Government Medical College, Kannauj, Uttar Pradesh. His role reflects his dedication to advancing multidisciplinary biomedical research with a focus on translational outcomes for healthcare.

Publications

Article: Computational insights into maternal environmental pollutants and folate pathway regulation
Authors: Adarsh Kumar Shukla, Shadab Ahamad, Prachi Kukshal
Journal: Reproductive Toxicology
Year: 2025

Article: Virtual screening of potential orally active anti-bacterial compounds of finger millet
Authors: Raushan Kumar Jha, Adarsh Kumar Shukla, Anita Kumari, Ashwani Kumar
Journal: Vegetos
Year: 2024

Article: Identification of micronutrient deficiency related miRNA and their targets in Triticum aestivum using bioinformatics approach
Authors: Surbhi Panwar, Sunita Pal, Adarsh Kumar Shukla, Ashwani Kumar, Pradeep Kumar Sharma
Journal: Ecological Genetics and Genomics
Year: 2024

Article: Effect of processing techniques on functional, antioxidants, and structural properties of finger millet (Eleusine coracana) flour
Authors: Arzoo, Neeru, Adarsh Kumar Shukla, Surbhi Panwar, Ashwani Kumar
Journal: Food and Humanity
Year: 2024

Article: Nutritional evaluation of probiotics enriched rabadi beverage (PERB) and molecular mapping of digestive enzyme with dietary fibre for exploring the therapeutic potential
Authors: Prakash Yadav, Adarsh Kumar Shukla, Deepika, Neeru, Anita Kumari, Tejpal Dhewa, Ashwani Kumar
Journal: Food and Humanity
Year: 2024

Conclusion

In summary, Dr. Shukla embodies the qualities of a multidisciplinary scientist who blends innovation with social responsibility. His research not only advances scientific understanding but also carries tangible implications for human health and nutrition. With his current role in a government medical research unit and his wide-ranging expertise, he is poised to make enduring contributions to biomedical sciences, food biotechnology, and public health.

Shahbaz Khan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Shahbaz Khan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Pharmacy Academy, Institute of Foreign Trade and Management University | India

Author Profile

Scopus

Orcid

Google Scholar

Early Academic Pursuits

Dr. Shahbaz Khan’s academic journey reflects a strong commitment to pharmaceutical sciences, beginning with foundational studies in pharmacy and advancing through specialized postgraduate training in pharmacology. His scholarly dedication culminated in a doctoral degree in pharmaceutical sciences, where his research explored the phytochemical and pharmacological activities of Betula alnoides bark extracts. These early academic achievements not only provided him with a robust understanding of pharmacological principles but also shaped his future research interests in neuropharmacology, neuroscience, and inflammation studies.

Professional Endeavors

Dr. Khan’s professional career spans diverse academic and administrative roles in reputed institutions. He has served as a faculty member in both assistant and associate professor capacities, mentoring students at undergraduate, postgraduate, and doctoral levels. Alongside his teaching and research responsibilities, he has contributed significantly to institutional development through administrative positions such as hostel warden. His teaching philosophy combines rigorous academic training with practical exposure, ensuring that his students are well-prepared for the pharmaceutical and healthcare industries.

Contributions and Research Focus

Dr. Khan’s research portfolio is extensive and multidisciplinary, with particular emphasis on neuropharmacology, phytochemistry, and inflammation-related pathologies. His studies delve into the therapeutic potential of medicinal plants, the development of advanced drug delivery systems, and the role of nutraceuticals in managing neurodegenerative and chronic diseases. His work also encompasses nanomedicine, regenerative medicine, and targeted therapies, leading to innovations in formulations and biomedical applications. By integrating modern pharmacological techniques with traditional medicinal knowledge, he has made meaningful contributions to both preclinical research and applied therapeutic strategies.

Accolades and Recognition

Dr. Khan has earned multiple national and international honors that recognize his academic excellence and research contributions. His achievements include prestigious travel grants for participating in global scientific programs organized by international brain research organizations, as well as awards for specialized training in molecular neuropharmacology. These recognitions underscore his role as a scholar of global repute and his ability to represent Indian pharmaceutical research on international platforms.

Impact and Influence

The impact of Dr. Khan’s work extends beyond his own research, influencing students, collaborators, and the broader scientific community. His publications in high-impact journals have contributed to advancing knowledge in pharmacology, medicinal chemistry, and biomedical sciences. His patents and innovations in pharmaceutical formulations highlight his ability to bridge the gap between laboratory research and practical healthcare solutions. Through book authorship and editorial contributions, he has also enriched the academic resources available to scholars worldwide.

Legacy and Future Contributions

Dr. Khan’s legacy lies in his ability to combine teaching, research, and innovation into a cohesive professional identity. His mentorship has guided many students toward successful careers in pharmacy and research. Looking ahead, he aims to expand his research in neurotherapeutics, nanomedicine, and herbal pharmacology, with a focus on developing novel, safe, and effective treatments for neurological and inflammatory disorders. His future contributions are expected to further strengthen the role of pharmaceutical sciences in addressing global health challenges.

Publications

Exploring Betula alnoides Bark: Insilico and Preclinical Insights into its Antioxidant and Lipid-Lowering Effects in Hypercholesterolemia
Authors: Shahbaz Khan, Alka Lohani, Prashant Tiwari, Sunil Kumar Kadiri
Journal: Obesity Medicine
Year: 2025

Innovative nanomedicine for fungal infections: Advancing treatments through nanotechnology and mycological approaches
Authors: Alka Lohani, Ritika Saxena, Shahbaz Khan, Ana Figueiras, Filipa Mascarenhas-Melo
Journal: Journal of Drug Delivery Science and Technology
Year: 2025

Tailored polymeric hydrogels for regenerative medicine and drug delivery: From material design to clinical applications
Authors: Alka Lohani, Ritika Saxena, Joana Galvão Duarte, Shahbaz Khan, Ana Figueiras, Filipa Mascarenhas-Melo
Journal: International Journal of Pharmaceutics
Year: 2025

pH-responsive IPN beads of carboxymethyl konjac glucomannan and sodium carboxymethyl cellulose as a controlled release carrier for ibuprofen
Authors: Alka Lohani, Ritika Saxena, Shahbaz Khan, Filipa Mascarenhas-Melo
Journal: International Journal of Biological Macromolecules
Year: 2024

An Insight Into Neuropathic Pain: A Systemic and Up-To-Date Review
Authors: Himanshu Sharma, Tanzeeb Rani, Shahbaz Khan
Journal: International Journal of Pharmaceutical Sciences and Research
Year: 2023

Conclusion

Through unwavering dedication to research, teaching, and innovation, Dr. Shahbaz Khan has established himself as a respected authority in pharmaceutical sciences. His contributions continue to inspire students, peers, and the scientific community at large, ensuring his place as a pivotal contributor to advancements in healthcare and pharmacology.

 

Mehlika Dilek Altıntop | Pharmacology, Toxicology and Pharmaceutical Science | Women Research Award

Published on by Book of Award

Prof Dr. Mehlika Dilek Altıntop | Pharmacology, Toxicology and Pharmaceutical Science | Women Research Award

Anadolu University | Turkey

Author Profile

Scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Mehlika Dilek Altıntop began her academic journey at İkieylül Elementary School (1991-1996) and continued at Eskişehir Anatolian High School (1996-2003). She pursued her undergraduate studies at Anadolu University, Faculty of Pharmacy (2003-2007). Following this, she completed her Master’s degree (with thesis) at Anadolu University, Graduate School of Health Sciences, Department of Pharmaceutical Chemistry (2007-2009). Her doctoral studies were also undertaken at Anadolu University, focusing on Pharmaceutical Chemistry (2009-2012).

Professional Endeavors 🏢

Dr. Altıntop’s professional career began as a Research Assistant at Anadolu University, Faculty of Pharmacy (2010-2012). She advanced to Research Assistant Doctor (2012-2014) and subsequently to Assistant Professor Doctor (2014-2015). She earned her position as Associate Professor Doctor (2015-2020) and was promoted to Professor Doctor (2020-present) at Anadolu University, Faculty of Pharmacy. Her administrative roles include serving as the Erasmus/Farabi/Mevlana Assistant Coordinator (2013-2014), Associate Director of Anadolu University Graduate School of Health Sciences (2014-2017 and 2023), and Quality Coordinator (2022-2023).

Contributions and Research Focus 🔬

Prof. Dr. Altıntop’s research predominantly focuses on pharmaceutical chemistry, medicinal chemistry, and drug development. She has made significant contributions to the synthesis and evaluation of novel compounds with therapeutic potential. Her work includes the development of dual EGFR and Akt inhibitors and small-molecule inhibitors targeting cancer therapy. She has also explored novel metabolic enzyme inhibitors and aldose reductase inhibitors.

Accolades and Recognition 🏆

Dr. Altıntop has received numerous awards for her academic and research achievements:

  • Anadolu University Faculty of Pharmacy Championship Award (2007)
  • Graduate Scholarship from The Scientific and Technological Research Council of Turkey (2007-2009)
  • Anadolu University Science and Technology Encouragement Award (2014)
  • Anadolu University Gold Article Performance Award (2015)
  • Turkish Pharmacists’ Association Academy of Pharmacy Encouragement Award (2019)
  • Outstanding Woman Researcher in Pharmaceutical Chemistry Award (VIWA 2021)
  • ISIF'21 Silver Medal for invention (2021)
  • Top Cited Article Awards (2021-2023)

Impact and Influence 🌟

Dr. Altıntop’s work has had a substantial impact on the field of pharmaceutical chemistry, particularly in the development of novel therapeutic agents for cancer and other diseases. Her role as an Associate Editor and Guest Editor in prestigious journals, as well as her involvement in international scientific committees, highlights her influence and leadership in the field.

Legacy and Future Contributions 🌐

Prof. Dr. Altıntop’s contributions continue to shape the future of pharmaceutical research and drug development. Her ongoing work in medicinal chemistry and her role in mentoring the next generation of researchers underscore her lasting legacy in advancing science and improving healthcare outcomes.

 

Publications

  • 📜Design, Synthesis, and Biological Evaluation of a New Series of Imidazothiazole-Hydrazone Hybrids as Dual EGFR and Akt Inhibitors for NSCLC Therapy
    Authors: Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, Ahmet Özdemir
    Journal: European Journal of Medicinal Chemistry
    Year: 2024

 

  • 📜Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents
    Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
    Journal: ACS Omega
    Year: 2024

 

  • 📜Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents
    Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
    Journal: ACS Omega
    Year: 2023

 

  • 📜Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy
    Authors: Erdoğan, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
    Journal: ACS Omega
    Year: 2023

 

  • 📜A New Series of Hydrazones as Small-Molecule Aldose Reductase Inhibitors
    Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
    Journal: Archiv der Pharmazie
    Year: 2023

 

  • 📜A New Series of Thiazole-Hydrazone Hybrids for Akt-Targeted Therapy of Non-Small Cell Lung Cancer
    Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
    Journal: Drug Development Research
    Year: 2023

Ahmet Özdemir | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Prof Dr. Ahmet Özdemir | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Anadolu University | Turkey

Author Profile

Scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Ahmet Özdemir's academic journey began at Salihli Cumhuriyet Elementary School (1978-1983), followed by Salihli 50. Yıl Secondary School (1983-1986) and Salihli High School (1986-1989). His passion for pharmacy led him to Anadolu University Faculty of Pharmacy, where he completed his undergraduate studies (1990-1994). He pursued further education at the Graduate School of Health Sciences, Department of Pharmaceutical Chemistry at Anadolu University, earning a Master's degree (1995-1996) and a Doctor's degree (1996-2004).

Professional Endeavors 💼

Prof. Dr. Özdemir's professional career commenced at Anadolu University as a Research Assistant (1997-2004). He progressed to Research Assistant Doctor (2004-2005), Lecturer (2005-2007), and Assistant Professor Doctor (2007-2010). His dedication and expertise earned him the title of Associate Professor Doctor (2010-2015), and he has been serving as a Professor Doctor since 2015.

Contributions and Research Focus 🔍

Prof. Dr. Özdemir's research is marked by significant contributions to pharmaceutical chemistry. His Master's thesis focused on "The studies on the synthesis, structure elucidations and determination of physicochemical parameters of some 2-substituted-1H-phenantro[9,10-d]imidazole compounds," under the supervision of Prof. Dr. İlhan Işıkdağ. His PhD thesis, supervised by Prof. Dr. Gülhan Turan, investigated the "Synthesis of some 1-[(N,N-disubstituted-thiocarbonylthio)acetyl]-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives and their antifungal, antibacterial activities."

Accolades and Recognition 🏅

Prof. Dr. Özdemir's work has been widely recognized, earning him numerous awards:

  • Anadolu University Article Performance Award (2014, 2016, 2017, 2018, 2020)
  • Anadolu University Gold Article Performance Award (2015)
  • Anadolu University Platinum Article Performance Award (2015)
  • Anadolu University Academic Success Award (2019)
  • ISIF'21 Silver Medal for the invention "Targeted Novel Triazolothiadiazine Derivatives for The Treatment of Lung Cancer" (2021)

Impact and Influence 🌟

Prof. Dr. Özdemir's impact extends beyond research. He has held key administrative roles, including Associate Director of Anadolu University Yunus Emre Vocational School (2011-2014) and Vice Academic Director of the Anadolu University Open Education Faculty, Department of Health Administration (2015-present). His mentorship has guided many students, as evidenced by his supervision of numerous master’s and doctoral dissertations.

Legacy and Future Contributions 🚀

Prof. Dr. Özdemir’s legacy is built on his unwavering commitment to advancing pharmaceutical chemistry. His innovative research, administrative leadership, and dedication to education have left an indelible mark on Anadolu University and the broader scientific community. As he continues his work, Prof. Dr. Özdemir is poised to make further groundbreaking contributions that will shape the future of pharmaceutical sciences.

 

Publications

📜Title: Design, Synthesis, and Biological Evaluation of a New Series of Imidazothiazole-Hydrazone Hybrids as Dual EGFR and Akt Inhibitors for NSCLC Therapy
Authors: Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, Ahmet Özdemir
Journal: European Journal of Medicinal Chemistry
Year: 2024

📜Title: Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents
Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
Journal: ACS Omega
Year: 2024

📜Title: Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents
Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
Journal: ACS Omega
Year: 2023

📜Title: Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy
Authors: Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
Journal: ACS Omega
Year: 2023

📜Title: A New Series of Hydrazones as Small-Molecule Aldose Reductase Inhibitors
Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
Journal: Archiv der Pharmazie
Year: 2023

📜Title: A New Series of Thiazole-Hydrazone Hybrids for Akt-Targeted Therapy of Non-Small Cell Lung Cancer
Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
Journal: Drug Development Research
Year: 2023